Novo Nordisk (NVO) is recovering after falling earlier this month on bad news from U.S. regulators. On Nov. 6, the drugmaker slumped 9% after the Food & Drug Administration warned of potential heart problems in its long-lasting insulin degludec. Since then, an FDA advisory panel has backed degludec and the company is now waiting for the agency's approval. The stock is back near levels where it fell earlier. But it's now grappling with upside